mixngo the disruptive technology, page-13

Surges - Lets say Anteo was involved with them now, what would the potential be??

Here is an exerpt from their website


Strategic alliances and collaborations are an important component of Quanterix�s overall business strategy. Quanterix is actively working with commercial partners to develop and validate bioassays that address unmet needs in life science research and in clinical diagnostics.

Quanterix is also partnering with clinical investigators to improve the performance of existing tests that may lead to new clinical utility in a variety of applications areas, and life science researchers to translate proteomic and expression array-based research into serum-based tests. With a 1000-fold sensitivity advantage, SiMoA can potentially measure hundreds to thousands of new biomarkers, creating a broad opportunity for validation of novel tests that may have diagnostic value.

Because the SiMoA platform is not yet commercially available, Quanterix is collaborating with investigators to develop, optimize and validate tests in Cambridge, MA for new and interesting biomarkers that could potentially benefit from increased sensitivity and precision. Through our Quanterix Translational Research Program (QTRP), we have established collaborations with clinical researchers to enable development of novel content in important areas with high unmet medical need.